The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Male aged 18 years or older at screening
Patient has provided written informed consent
Histologically confirmed prostate adenocarcinoma w
Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgery
Prior systemic therapy for metastatic prostate cancer. Prior ADT is allowed but ADT within 6 months of screening for the study is not allowed. If patients have received prior ADT, serum testosterone levels must be above the lower limit of normal
Any visceral (AJCCC M1c) metastases
Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
Peter MacCallum Cancer Centre, Australia
Lead sponsor
Varian Medical Systems
Collaborator